Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

Complement factor B (CFB) inhibitors are described in a Novartis AG patent and reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy and eye disorders, ...

The FDA approved iptacopan for treatment of adults with paroxysmal nocturnal hemoglobinuria. Iptacopan (Fabhalta, Novartis) is an oral selective complement factor B inhibitor designed to be given as ...

Sitala Bio Ltd. has divulged complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, schizophrenia, atypical hemolytic uremic syndrome, ...

Researchers discover a link between an increase in protein Ba of the complement immune system and the eventual development of thrombotic microangiopathy in patients who have received an allogeneic ...